Biomarkers in Rare Disorders: The Experience with Spinal Muscular Atrophy
Author Information
Author(s): Tiziano Francesco D., Neri Giovanni, Brahe Christina
Primary Institution: Institute of Medical Genetics, Catholic University of Sacro Cuore, Roma, Italy
Hypothesis
Can biomarkers be reliably used to evaluate the clinical outcomes in spinal muscular atrophy (SMA)?
Conclusion
No single biomarker has been established as the gold standard for spinal muscular atrophy, but some, like MUNE and SMN transcript quantification, show promise.
Supporting Evidence
- Different biomarkers have been proposed for SMA, but none are considered definitive.
- Electrophysiological measures like CMAP and MUNE show potential but have limitations.
- SMN protein levels correlate with disease severity but are not reliable for individual prognosis.
- Clinical trials need to address the natural history of SMA and the reliability of outcome measures.
Takeaway
Spinal muscular atrophy is a disease that affects muscles, and researchers are trying to find reliable tests to see how well treatments work.
Methodology
The study reviews various biomarkers for SMA, including instrumental and molecular types, and discusses their potential in clinical trials.
Limitations
None of the biomarkers can be considered the gold standard, and there are still unresolved issues regarding their reliability and clinical relevance.
Participant Demographics
The study includes SMA patients of varying severity, with a focus on types I to III.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website